Ubiquitin ligase A20 regulates p53 protein in human colon epithelial cells

Journal of Biomedical Science

Ziqi Zhang²  Xiao Chen²  Zhiqiang Wang²  Shaobo Yang¹  Jing Liu² 

[1] Department of Gastroenterology, Division of South Building, Chinese PLA general hospital, Beijing 100853, China;Department of Digestive Endoscopy, Division of South Building, Chinese PLA general hospital, Beijing 100853, China

关键词: Colon polyp;    P53 protein;    Ubiquitin E3 ligase A20;    Cancer;    Colon;   

Others  :  823206
DOI  :  10.1186/1423-0127-20-74

 received in 2013-02-08, accepted in 2013-10-06,  发布年份 2013

【 摘 要 】

Background

Intestinal polyps may further develop into colon cancer; the pathogenesis is not clear. The p53 gene is an important anti-cancer gene in the body, which is suppressed in cancer. The ubiquitin E3 ligase A20 (A20) plays a role in regulating the activities of epithelial cells. This study was designed to investigate the role of the colon polyp epithelium-derived A20 in the pathogenesis of colon cancer.

Results

Eighty-eight colon cancer patients and 136 colon polyp patients were recruited into this study. Human colon cancer tissue, the epithelium of adenomas polyp and hyperplastic polyp showed high levels of A20, which had a positive correlation with the cancerous tendency of colon polyps. The levels of A20 were much higher in the adenomas and hyperplastic polyps than that in the inflammatory polyps; the latter showed less cancerous tendency. A20 bound p53 to form complexes in colon cancer tissue and colon polyps. Over expression of A20 suppresses P53 protein levels in the HEK293 cells.

Conclusions

A20 may play an important role in the cancerous tendency of colon polyposis.

【 授权许可】

   
2013 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer Statistics, 2009. CA Canc J Clin 2009, 59:225-249.
• [2]Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LAG: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
• [3]Richards CA, Kerker BD, Thorpe L, Olson C, Krauskopf MS, Silver LS, Weber TK, Winawer SJ: Increased Screening Colonoscopy Rates and Reduced Racial Disparities in the New York Citywide Campaign: An Urban Model. Am J Gastroenterol 2011, 106:1880-1886.
• [4]Weir HK, Thun MJ, Hankey BF, Ries LAG, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK: Annual Report to the Nation on the Status of Cancer, 1975Γ€“2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control. J Natl Canc Inst 2003, 95:1276-1299.
• [5]Arya M, Patel HRH, Williamson M: Chemokines: key players in cancer. Curr Med Res Opin 2003, 19:557-564.
• [6]Hu B, Elinav E, Flavell RA: Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle 2011, 10:1936-1939.
• [7]Coe SGWM: Management of small and diminutive colorectal polyps: a review of the literature. Minerva Gastroenterol Dietol 2011, 57:167-176.
• [8]Teriaky A, Driman DK, Chande N: Outcomes of a 5-year follow-up of patients with sessile serrated adenomas. Scand J Gastroenterol 2012, 47:178-183.
• [9]Miwa S, Mitomi H, Igarashi M, Kobayashi K, Katsumata T, Ihara A, Otani Y, Ojima T, Saigenji K: Clinicopathologic differences among subtypes of serrated adenomas of the colorectum. Hepatogastroenterology 2005, 52:437-440.
• [10]Fu L, Lee CC: The circadian clock: pacemaker and tumour suppressor. Nat Rev Canc 2003, 3:350-361.
• [11]Iniesta P, Vega FJ, Caldés T, Massa M, de Juan C, Cerdán FJ, Sánchez A, López JA, Torres AJ, Balibrea JL, Benito M: p53 Exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Canc Lett 1998, 130:153-160.
• [12]Samowitz WS, Curtin K, Ma K, Edwards S, Schaffer D, Leppert MF, Slattery ML: Prognostic significance of p53 mutations in colon cancer at the population level. Int J Canc 2002, 99:597-602.
• [13]Jernvall P, Mäkinen M, Karttunen T, Mäkelä J, Vihko P: Conserved region mutations of the p53 gene are concentrated in distal colorectal cancers. Int J Canc 1997, 74:97-101.
• [14]Børresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E: TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Canc Res 1998, 4:203-210.
• [15]Wang M, Li S: Bladder Polypoid Cystitis-Derived A20 Associates with Tumorigenesis. Cell Biochem Biophys 2013, 66:1-5.
• [16]Vucic D, Dixit VM, Wertz IE: Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011, 12:439-452.
• [17]Byrne WL, Mills KHG, Lederer JA, O’Sullivan GC: Targeting Regulatory T Cells in Cancer. Canc Res 2011, 71:6915-6920.
• [18]Hymowitz SG, Wertz IE: A20: from ubiquitin editing to tumour suppression. Nat Rev Canc 2010, 10:332-341.
• [19]Bobe G, Murphy G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Cross AJ: Dietary lignan and proanthocyanidin consumption and colorectal adenoma recurrence in the Polyp Prevention Trial. Int J Canc 2012, 130:1649-1659.
• [20]Burnett-Hartman AN, Newcomb PA, Phipps AI, Passarelli MN, Grady WM, Upton MP, Zhu LC, Potter JD: Colorectal Endoscopy, Advanced Adenomas, and Sessile Serrated Polyps: Implications for Proximal Colon Cancer. Am J Gastroenterol 2012, 107:1213-1219.
• [21]Messick CA, Church J, Bennett A, Kalady MF: Serrated polyps: new classifications highlight clinical importance. Colorectal Dis 2012, 14:1328-37.
• [22]Shembade N, Harhaj EW: Regulation of NF-[kgr]B signaling by the A20 deubiquitinase. Cell Mol Immunol 2012, 9:123-130.
• [23]DiDonato JA, Mercurio F, Karin M: NF-kappa B and the link between inflammation and cancer. Immunol Rev 2012, 246:379-400.
• [24]Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A: Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol 2011, 12:1184-1193.
• [25]Kool M, van-áLoo G, Waelput W, De-áPrijck S, Muskens F, Sze M, van-áPraet J, Branco-Madeira F, Janssens S, Reizis B, Elewaut D, Beyaert R, Hammad H, Lambrecht B: The Ubiquitin-Editing Protein A20 Prevents Dendritic Cell Activation, Recognition of Apoptotic Cells, and Systemic Autoimmunity. Immunity 2011, 35:82-96.
• [26]Song CH, Liu ZQ, Huang S, Zheng PY, Yang PC: Probiotics promote endocytic allergen degradation in gut epithelial cells. Biochem Biophys Res Commun 2012, 426:135-140.
• [27]Huang P, Geng XR, Yang G, Chen C, Liu Z, Yang PC: Ubiquitin E3 Ligase A20 Contributes to Maintaining Epithelial Barrier Function. Cell Physiol Biochem 2012, 30:702-710.
• [28]Arriaga JM, Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, Pairola F, Huertas E, Roberti MP, Rocca YS, Aris M, Barrio MM, Baffa Trasci S, Levy EM, Mordoh J, Bianchini M: Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer. Hum Pathol 2012, 43:1695-1703.
• [29]Wade M, Li YC, Wahl GM: MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Canc 2013, 13:83-96.